Eledon Pharmaceuticals (ELDN) Times Interest Earned (2013 - 2026)
Eledon Pharmaceuticals (ELDN) posted Times Interest Earned of -$211.81 for Q1 2026, down 783.0% on a QoQ basis from -$23.99 in Q3 2025, and down 1067.29% year-over-year from $21.9 in Q1 2025.
Eledon Pharmaceuticals (ELDN) Times Interest Earned (2013 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Times Interest Earned history runs 14 years deep, the most recent figure standing at -$211.81 for Q1 2026.
- Quarterly Times Interest Earned fell 1067.29% year-over-year to -$211.81 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$205.32 (down 161.69% YoY) and the FY2025 annual result came in at $0.28, up 118.17% from the prior year.
- Times Interest Earned was -$211.81 for Q1 2026 at Eledon Pharmaceuticals, down from -$23.99 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$12.27 in Q3 2022 and bottomed at -$605.03 in Q4 2022.
- A 5-year average of -$101.45 and a median of -$31.81 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2022 — Times Interest Earned surged 99.53% — and 2026, when it slumped 1067.29%.
- Eledon Pharmaceuticals' Times Interest Earned stood at -$605.03 in 2022, then jumped by 82.74% to -$104.42 in 2023, then tumbled by 123.11% to -$232.98 in 2024, then surged by 89.7% to -$23.99 in 2025, then slumped by 783.0% to -$211.81 in 2026.
- Business Quant data shows ELDN's Times Interest Earned at -$211.81 in Q1 2026, -$23.99 in Q3 2025, and -$27.7 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -157.58 |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | 3.88 |
| 10 | Eledon Pharmaceuticals | 404.17 Mn | 404.17 Mn | - | -211.81 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -211.81 |
| Sep 30, 2025 | -23.99 |
| Jun 30, 2025 | -27.70 |
| Mar 31, 2025 | -18.15 |
| Dec 31, 2024 | -232.98 |
| Sep 30, 2024 | -35.92 |
| Jun 30, 2024 | -21.55 |
| Mar 31, 2024 | -37.87 |
| Dec 31, 2023 | -104.42 |
| Sep 30, 2023 | -22.99 |
| Jun 30, 2023 | -17.70 |
| Mar 31, 2023 | -133.86 |
| Dec 31, 2022 | -605.03 |
| Sep 30, 2022 | -12.27 |
| Jun 30, 2022 | -15.32 |
| Mar 31, 2022 | -101.64 |
| Dec 31, 2021 | -151.37 |
| Sep 30, 2021 | -2,626.50 |
| Jun 30, 2021 | -28.99 |
| Mar 31, 2021 | -183.78 |